Alkylating agents
Chemotherapy + Radiation Therapy for Brain Cancer
Recruiting1 awardPhase 2
Madera, California
This trial is studying how well different combinations of chemotherapy and radiation therapy work in treating patients with non-germinomatous germ cell tumors that have not spread to other parts of the brain or body.
Topoisomerase I inhibitors
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
Recruiting2 awardsPhase 1
Houston, Texas
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Genitourinary Cancers
Recruiting1 awardPhase 2
La Jolla, California
This trial is studying a combination of two drugs, Nivolumab and Ipilimumab, as a possible treatment for rare genitourinary cancers. Bladder and upper tract carcinomas with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas, and any genitourinary carcinoma with neuroendocrine differentiation are being studied. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time.
Popular Filters
Trials for Cancer Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
CAR T-cell Therapy
CAR T-Cell Therapy for Pediatric Cancer
Recruiting1 awardPhase 1
Memphis, Tennessee
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
Trials for Adenocarcinoma Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials for Metastatic Patients
Chemotherapy
PT-112 Injection for Advanced Prostate Cancer
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials With No Placebo
Behavioural Intervention
Virtual Active Surveillance for Testicular Cancer
Recruiting1 award6 criteria
Toronto, Ontario
This trial is testing WATChmAN, an online system for testicular cancer patients to manage their follow-up care virtually. It aims to make follow-ups easier and more convenient by reducing the need for regular hospital visits. Patients will receive reminders, check their results, and communicate with doctors through the platform.
Platinum-containing Compound
Chemotherapy and Stem Cell Transplant for Germ Cell Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This study is evaluating whether a combination of chemotherapy and a stem cell transplant is more effective than chemotherapy alone in treating patients with germ cell tumors.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.